Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). Synergistic effects of conventional agents with checkpoint inhibition may facilitate a highly effective therapy with limited toxicity, which might eventually substitute the very toxic high-dose chemotherapy (HDCT).

Trial Details

NCT ID

NCT04838652

Phase

PHASE2

Sponsor

University of Cologne

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Pembrolizumab plus Chemotherapy (ICE or DHAP)

Locations (sample)

• Cologne, Germany|50.93333,6.95

Key Eligibility Criteria

• Histologically confirmed first relapse of cHL or primary refractory cHL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →